Moderna falls as waning demand for COVID-19 vaccines hit sales, profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Moderna (MRNA) changes point to an 'extended period of underperformance' - SVB Securities
February 24, 2023 10:16 AM ESTModerna (NASDAQ: MRNA) was cut to Underperform from Market Perform by SVB Securities analyst Mani Foroohar on Friday.
Foroohar also lowered the firm's price target on the stock to $93 from $111 following Thursday's reported FY22 results and updated 2023 guidance which "gave a deeper... More
Moderna (MRNA) PT Lowered to $185 at Morgan Stanley Following EPS
February 23, 2023 12:39 PM ESTMorgan Stanley analyst Matthew Harrison lowered the price target on Moderna (NASDAQ: MRNA) to $185.00 (from $205.00) while maintaining a Overweight rating following earnings.
The analyst commented, "4Q22 was generally in-line. 2023 COGS of 35-40% was above expectations and the most notable downside driver in our... More
